Appointment of Chief Financial Officer and Company Secretary

Compumedics Limited (ASX: CMP) is pleased to announce the appointment of its Deputy Chief Financial Officer, Mr Troy Lamb, as Chief Financial Officer and Company Secretary, effective 1 November 2026.

Mr Lamb succeeds Mr David Lawson, who will continue as Finance Director and remain an active member of the Company's executive leadership team. Drawing on 26 years' experience with Compumedics and a deep understanding of the business, Mr Lawson will work closely with the Board, CEO and Mr Lamb on the Company's financial strategy, business operations and key growth initiatives.

Mr Lamb brings more than 20 years of financial and commercial experience across ASX-listed, private equity-backed and multinational organisations. He combines expertise in financial strategy and capital management with a strong track record of improving commercial performance and leading business transformation. Since joining Compumedics as Deputy Chief Financial Officer in March 2025, he has worked closely with Mr Lawson and the executive team in leading the Group's global finance operations, including through the delivery of the Company's record FY26 result. Mr Lamb is a Chartered Accountant and holds an MBA from Melbourne Business School.

Executive Chairman and Chief Executive Officer, Dr David Burton, said:

> *"This planned succession builds on the strength of our finance leadership. Troy brings substantial financial and commercial experience, a strong understanding of our global operations and a clear focus on business performance.*
>
> *"David remains an integral member of our executive leadership team and will continue to play an active role in shaping the Company's strategy and growth. His ongoing leadership as Finance Director, alongside Troy's leadership of the finance function, provides the continuity and capability to support our growth ambitions and build long-term shareholder value."*
>
> **Dr David Burton** - Executive Chairman and Chief Executive Officer

From 1 November 2026, Mr Lamb will also be the person responsible for communications with ASX on Listing Rule matters.

ABOUT COMPUMEDICS LIMITED

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the USA, and DWL Elektronische Systeme GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

FOR FURTHER INFORMATION, PLEASE CONTACT

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: +61 3 8420 7300
F: +61 3 8420 7399

This announcement has been authorised for release by the Board of Directors of Compumedics Limited.